These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 26169213)

  • 1. Predictive biomarker candidates to delineate efficacy of antiangiogenic treatment in renal cell carcinoma.
    Romero-Laorden N; Doger B; Hernandez M; Hernandez C; Rodriguez-Moreno JF; Garcia-Donas J
    Clin Transl Oncol; 2016 Jan; 18(1):1-8. PubMed ID: 26169213
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Resistance to sunitinib in renal cell carcinoma: From molecular mechanisms to predictive markers and future perspectives.
    Joosten SC; Hamming L; Soetekouw PM; Aarts MJ; Veeck J; van Engeland M; Tjan-Heijnen VC
    Biochim Biophys Acta; 2015 Jan; 1855(1):1-16. PubMed ID: 25446042
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Constitutional genetic variants as predictors of antiangiogenic therapy outcome in renal cell carcinoma.
    Rodríguez-Antona C; García-Donas J
    Pharmacogenomics; 2012 Nov; 13(14):1621-33. PubMed ID: 23148638
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Myopodin methylation is a prognostic biomarker and predicts antiangiogenic response in advanced kidney cancer.
    Pompas-Veganzones N; Sandonis V; Perez-Lanzac A; Beltran M; Beardo P; Juárez A; Vazquez F; Cozar JM; Alvarez-Ossorio JL; Sanchez-Carbayo M
    Tumour Biol; 2016 Oct; 37(10):14301-14310. PubMed ID: 27592258
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The role of angiogenesis in renal carcinoma].
    Bussolati B; Satolli MA; Camussi G
    G Ital Nefrol; 2008; 25(3):297-305. PubMed ID: 18473301
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emerging antiangiogenics for renal cancer.
    Domblides C; Gross-Goupil M; Quivy A; Ravaud A
    Expert Opin Emerg Drugs; 2013 Dec; 18(4):495-511. PubMed ID: 24274612
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evidence and Clinical Relevance of Tumor Flare in Patients Who Discontinue Tyrosine Kinase Inhibitors for Treatment of Metastatic Renal Cell Carcinoma.
    Iacovelli R; Massari F; Albiges L; Loriot Y; Massard C; Fizazi K; Escudier B
    Eur Urol; 2015 Jul; 68(1):154-60. PubMed ID: 25466943
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reappraisal of the role of bevacizumab in the therapeutic strategy in advanced renal cell carcinoma.
    Guillot A; Levy A; Pacaut C; Collard O; Massard C; Merrouche Y; Magné N
    Clin Genitourin Cancer; 2012 Sep; 10(3):147-52. PubMed ID: 22796529
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factors associated with outcome in patients with advanced renal cell carcinoma in the era of antiangiogenic agents.
    Choueiri TK
    Clin Genitourin Cancer; 2008 Mar; 6(1):15-20. PubMed ID: 18501077
    [TBL] [Abstract][Full Text] [Related]  

  • 10. von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma.
    Choueiri TK; Vaziri SA; Jaeger E; Elson P; Wood L; Bhalla IP; Small EJ; Weinberg V; Sein N; Simko J; Golshayan AR; Sercia L; Zhou M; Waldman FM; Rini BI; Bukowski RM; Ganapathi R
    J Urol; 2008 Sep; 180(3):860-5; discussion 865-6. PubMed ID: 18635227
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma.
    Rini BI; Michaelson MD; Rosenberg JE; Bukowski RM; Sosman JA; Stadler WM; Hutson TE; Margolin K; Harmon CS; DePrimo SE; Kim ST; Chen I; George DJ
    J Clin Oncol; 2008 Aug; 26(22):3743-8. PubMed ID: 18669461
    [TBL] [Abstract][Full Text] [Related]  

  • 12. miR-221/222 Are Involved in Response to Sunitinib Treatment in Metastatic Renal Cell Carcinoma.
    Khella HWZ; Butz H; Ding Q; Rotondo F; Evans KR; Kupchak P; Dharsee M; Latif A; Pasic MD; Lianidou E; Bjarnason GA; Yousef GM
    Mol Ther; 2015 Nov; 23(11):1748-1758. PubMed ID: 26201448
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bevacizumab as first-line therapy for patients with brain metastases from renal carcinoma: a case series.
    Zustovich F; Ferro A; Farina P
    Clin Genitourin Cancer; 2014 Jun; 12(3):e107-10. PubMed ID: 24583162
    [No Abstract]   [Full Text] [Related]  

  • 14. Tumoral cubilin is a predictive marker for treatment of renal cancer patients with sunitinib and sorafenib.
    Niinivirta M; Enblad G; Edqvist PH; Pontén F; Dragomir A; Ullenhag GJ
    J Cancer Res Clin Oncol; 2017 Jun; 143(6):961-970. PubMed ID: 28260162
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Perspective: What next for treatment?
    Motzer RJ
    Nature; 2016 Sep; 537(7620):S111. PubMed ID: 27626781
    [No Abstract]   [Full Text] [Related]  

  • 16. The Association Between PD-L1 Expression and the Clinical Outcomes to Vascular Endothelial Growth Factor-Targeted Therapy in Patients With Metastatic Clear Cell Renal Cell Carcinoma.
    Shin SJ; Jeon YK; Cho YM; Lee JL; Chung DH; Park JY; Go H
    Oncologist; 2015 Nov; 20(11):1253-60. PubMed ID: 26424759
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predicting outcome to VEGF-targeted therapy in metastatic clear-cell renal cell carcinoma: data from recent studies.
    Golshayan AR; Brick AJ; Choueiri TK
    Future Oncol; 2008 Feb; 4(1):85-92. PubMed ID: 18241003
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biomarkers predicting outcome in patients with advanced renal cell carcinoma: Results from sorafenib phase III Treatment Approaches in Renal Cancer Global Evaluation Trial.
    Peña C; Lathia C; Shan M; Escudier B; Bukowski RM
    Clin Cancer Res; 2010 Oct; 16(19):4853-63. PubMed ID: 20651059
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictive biomarkers in renal cell cancer: insights in drug resistance mechanisms.
    van der Mijn JC; Mier JW; Broxterman HJ; Verheul HM
    Drug Resist Updat; 2014; 17(4-6):77-88. PubMed ID: 25457974
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sunitinib, sorafenib and mTOR inhibitors in renal cancer.
    Radulovic S; Bjelogrlic SK
    J BUON; 2007 Sep; 12 Suppl 1():S151-62. PubMed ID: 17935273
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.